Cart
sales@molnova.com
Befotertinib
CAS No. 1835667-63-4
Befotertinib( D-0316 )
Catalog No. M28217 CAS No. 1835667-63-4
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 222 | Get Quote |
|
| 10MG | 357 | Get Quote |
|
| 25MG | 597 | Get Quote |
|
| 50MG | 851 | Get Quote |
|
| 100MG | 1152 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBefotertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
In Vitro——
-
In Vivo——
-
SynonymsD-0316
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorCDK2|CDK5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1835667-63-4
-
Formula Weight567.61
-
Molecular FormulaC29H32F3N7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (88.09 mM)
-
SMILESC=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ka?mierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214.
molnova catalog
related products
-
Afatinib
An irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively.
-
Petosemtamab
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption and receptor breakdown in LGR5+ cancer cells.
-
EGFR-IN-8
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
